{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:59Z","timestamp":1789013459757,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11899-017-0375-0","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T14:45:28Z","timestamp":1492008328000},"page":"79-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Role of Early Molecular Response in the Management of Chronic Phase CML"],"prefix":"10.1007","volume":"12","author":[{"given":"Patrick","family":"Harrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytug","family":"Kizilors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"de Lavallade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,12]]},"reference":[{"issue":"15","key":"375_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451\u201364. doi: 10.1056\/NEJMra020777 .","journal-title":"N Engl J Med"},{"issue":"7","key":"375_CR2","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","volume":"61","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61(7):1441\u20136.","journal-title":"Cancer"},{"issue":"21","key":"375_CR3","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","volume":"125","author":"AJ Barrett","year":"2015","unstructured":"Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125(21):3230\u20135. doi: 10.1182\/blood-2014-10-567784 .","journal-title":"Blood"},{"issue":"6","key":"375_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384. doi: 10.1182\/blood-2013-05-501569 .","journal-title":"Blood"},{"issue":"20","key":"375_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/jco.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(20):2333\u201340. doi: 10.1200\/jco.2015.64.8899 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"375_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317. doi: 10.1056\/NEJMoa062867 .","journal-title":"N Engl J Med"},{"issue":"5","key":"375_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354. doi: 10.1038\/leu.2016.5 .","journal-title":"Leukemia"},{"issue":"1","key":"375_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/asheducation-2012.1.115","volume":"2012","author":"D Marin","year":"2012","unstructured":"Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. ASH Education Program Book. 2012;2012(1):115\u201321. doi: 10.1182\/asheducation-2012.1.115 .","journal-title":"ASH Education Program Book"},{"issue":"1","key":"375_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337. doi: 10.1182\/blood-2006-01-0092 .","journal-title":"Blood"},{"issue":"35","key":"375_CR10","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(35):6041\u201351. doi: 10.1200\/JCO.2009.25.0779 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"375_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"\u2022\u2022 Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999\u20131003. doi: 10.1038\/leu.2015.29 .","journal-title":"Leukemia"},{"issue":"4","key":"375_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494\u2013500. doi: 10.1182\/blood-2013-06-511592 .","journal-title":"Blood"},{"issue":"11","key":"375_CR13","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","volume":"92","author":"FX Mahon","year":"1998","unstructured":"Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood. 1998;92(11):4059\u201365.","journal-title":"Blood"},{"issue":"9","key":"375_CR14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","volume":"16","author":"K Merx","year":"2002","unstructured":"Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16(9):1579\u201383. doi: 10.1038\/sj.leu.2402680 .","journal-title":"Leukemia"},{"issue":"6","key":"375_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120(6):990\u20139.","journal-title":"Br J Haematol"},{"issue":"20","key":"375_CR16","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(20):3358\u201363. doi: 10.1200\/JCO.2007.15.8154 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"375_CR17","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758\u201365. doi: 10.1182\/blood-2010-03-273979 .","journal-title":"Blood"},{"issue":"3","key":"375_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"\u2022\u2022 Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):232\u20138. doi: 10.1200\/JCO.2011.38.6565 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"375_CR19","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"\u2022\u2022 Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u2013102. doi: 10.1038\/leu.2012.85 .","journal-title":"Leukemia"},{"issue":"2","key":"375_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"\u2022 Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120(2):291\u20134. doi: 10.1182\/blood-2012-01-407486 .","journal-title":"Blood"},{"issue":"9","key":"375_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353\u201360. doi: 10.1182\/blood-2013-06-510396 .","journal-title":"Blood"},{"issue":"24","key":"375_CR22","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121(24):4867\u201374. doi: 10.1182\/blood-2013-03-490128 .","journal-title":"Blood"},{"issue":"3","key":"375_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ejh.12423","volume":"94","author":"H Hjorth-Hansen","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94(3):243\u201350. doi: 10.1111\/ejh.12423 .","journal-title":"Eur J Haematol"},{"issue":"14","key":"375_CR24","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"\u2022 Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013;121(14):2739\u201342. doi: 10.1182\/blood-2012-11-466037 .","journal-title":"Blood"},{"issue":"6","key":"375_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ajh.23707","volume":"89","author":"DD Kim","year":"2014","unstructured":"Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014;89(6):626\u201332. doi: 10.1002\/ajh.23707 .","journal-title":"Am J Hematol"},{"key":"375_CR26","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C et al. Comparing the prognostic significance of early predictors of survival in chronic myeloid leukemia (CML) treated with imatinib\u2014an analysis of the randomized CML-study IV. Blood. 2014; 124(21):156-.","DOI":"10.1182\/blood.V124.21.156.156"},{"issue":"4","key":"375_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"\u2022\u2022 Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511\u20138. doi: 10.1182\/blood-2014-03-566323 .","journal-title":"Blood"},{"issue":"10","key":"375_CR28","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"\u2022\u2022 Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28(10):1988\u201392. doi: 10.1038\/leu.2014.153 .","journal-title":"Leukemia"},{"issue":"4","key":"375_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90(4):282\u20137. doi: 10.1002\/ajh.23923 .","journal-title":"Am J Hematol"},{"issue":"11","key":"375_CR30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335. doi: 10.1016\/S1470-2045(10)70233-3 .","journal-title":"Lancet Oncol"},{"issue":"4","key":"375_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322. doi: 10.1182\/blood-2013-02-483750 .","journal-title":"Blood"},{"issue":"5","key":"375_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5):424\u201330. doi: 10.1200\/JCO.2012.48.5797 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"375_CR33","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"\u2022 Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818\u201324. doi: 10.1182\/blood-2012-10-462291 .","journal-title":"Blood"},{"issue":"3","key":"375_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489\u201398. doi: 10.1182\/blood-2012-05-431379 .","journal-title":"Blood"},{"issue":"8","key":"375_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513\u201326. doi: 10.1038\/nrc3317 .","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"375_CR36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208\u201315. doi: 10.1182\/blood-2010-12-326405 .","journal-title":"Blood"},{"issue":"29","key":"375_CR37","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","volume":"26","author":"JS Khorashad","year":"2008","unstructured":"Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(29):4806\u201313. doi: 10.1200\/JCO.2008.16.9953 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"375_CR38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood.V126.23.347.347","volume":"126","author":"A Kizilors","year":"2015","unstructured":"Kizilors A, Crisa E, Lea N, Best S, Syed M, Ireland RM, et al. Impact of finding of low level kinase domain mutations using ultra deep next generation sequencing in patients with chronic phase CML. Blood. 2015;126(23):347.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0375-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0375-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0375-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T11:20:38Z","timestamp":1601896838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0375-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0375-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}